CLASS III Drug recall · Reported 30 Apr 2014 · FDA Enforcement Report

Nicotine polacrilex lozenge, 2 mg recalled by GlaxoSmithKline Consumer

GlaxoSmithKline Consumer Healthcare; is recalling Nicotine polacrilex lozenge, 2 mg, Cherry Flavor vials vials, and vials, distributed nationwide in the US. The recall was initiated on 20 Feb 2014 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLabeled A) 72 Ct Vial: Lot #13468 (exp 4/14), 13618 (exp 6/14) & 14105 (exp 2/15); 81 Ct- Vial, Lot #13815 (exp 10/14), 13864 (exp 11/14) & 13941 (exp 12/14); 108 Ct- Vial, Lot # 13574 (exp 7/14). Labeled B) 72 Ct Vial, Lot #13573 (exp 6/14) & 14257 (exp 7/15). Labeled C) 72 Ct Vial: Lot # 13875 (exp 5/14), 13642 (exp 7/14), 13770 (exp 8/14) & 13875 (exp 11/14).
Quantity recalled109,848 72 Ct Vials, 61,332 81 Ct Vials, 16,218 108 Ct Vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1238-2014
FDA event ID
67800
Recalling firm
GlaxoSmithKline Consumer Healthcare;, Aiken, SC
Classification
Class III
Status
Terminated
Recall initiated
20 Feb 2014
FDA classified
18 Apr 2014
Reported
30 Apr 2014
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

20 Feb 2014Recall initiated by company
18 Apr 2014Classified by FDA+57 days
30 Apr 2014Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Nicotine polacrilex lozenge, 2 mg, Cherry Flavor, 72 count vials, 81 count vials, and 108 count vials. OTC. Labeled a. Nicorette, Distributed By: GlaxoSmithKline Consumer Healthcare, L.P., Moon Township, PA 15108. Made in Switzerland. 72 Count NDC: 0135-0512-01, 81 Count NDC: 0135-0512-02, 108 Count NDC: 0135-0512-03 b. Nicotine Lozenge Kroger, Distributed by: The Kroger Company, Cincinnati, Ohio 45202, 72 Count NDC:30142-663-01, and c. Nicotine Walgreens, Distributed by: Walgreen Co., 200 Wilmot Rd., Deerfield, IL 60015. 72 Count NDC: 0363-0446-01.

Where it was distributed

U.S. Nationwide

Nationwide

Stores named: Kroger, Walgreens

Questions about this recall

Is Nicotine polacrilex lozenge, 2 mg, Cherry Flavor vials vials, and vials recalled?

Yes. GlaxoSmithKline Consumer Healthcare; recalled Nicotine polacrilex lozenge, 2 mg, Cherry Flavor vials vials, and vials on 20 Feb 2014. The recall is Class III and its status is Terminated. Recall number D-1238-2014.

Why was it recalled?

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Which lots are affected?

Labeled A) 72 Ct Vial: Lot #13468 (exp 4/14), 13618 (exp 6/14) & 14105 (exp 2/15); 81 Ct- Vial, Lot #13815 (exp 10/14), 13864 (exp 11/14) & 13941 (exp 12/14); 108 Ct- Vial, Lot # 13574 (exp 7/14). Labeled B) 72 Ct Vial, Lot #13573 (exp 6/14) & 14257 (exp 7/15). Labeled C) 72 Ct Vial: Lot # 13875 (exp 5/14), 13642 (exp 7/14), 13770 (exp 8/14) & 13875 (exp 11/14).

Where was it sold?

U.S. Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from GlaxoSmithKline Consumer Healthcare;

All 10